Clinical Trial Update: Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy and safety of aprepitant in multiple myeloma patients during and after high-dose chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Heidelberg University | Conditions: Multiple Myeloma | Phase 3 | Status: UNKNOWN